Loading...
Biosimilar Adoption And Cost Reductions Will Support Long Term Earnings Recovery
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
1Y
-56.6%7D
3.4%1Y
-56.6%7D
3.4%You can edit this narrative until Dec 8 7:03 AM. Then, changes will post as Updates.